Please assess the completion status of the following clinical trial:

Trial Title: Study of Acamprosate in Driving Under the Influence (DUI) Court Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult males and females age 18 - 64 years of age~2. District Attorney-approved DUI Court participants within 3 months of enrollment into DUI Court~3. Currently meets DSM-IV criteria for alcohol dependence~4. Subject agrees to alcohol abstinence as a goal~5. Women must agree to use an approved method of birth control (tubal ligation, birth control pills, IUD)~6. Negative UCG (females only)~7. Treatment with an MAOI, other antidepressants, antipsychotics, anticonvulsants, mood stabilizers, or Saint John's Wort are permissible if subject has been on a stable dose for 3 months~8. Must have the ability to comprehend key components of the informed consent and provide consent~9. Current score of 15 or less on the Beck Depression Inventory II~10. Subject has undergone detoxification and is currently abstinent from alcohol~Exclusion Criteria:~1. History of allergy to acamprosate~2. Previously failed trial of acamprosate~3. Pregnancy, lactation, or unprotected intercourse during study period~4. Lifetime diagnosis of schizophrenia or schizoaffective disorder~5. Creatinine clearance \<30 mL/minute. If serum creatinine is greater than 1.4 mg/dL then the Cockcroft-Gault equation will be used to estimate creatinine clearance~6. Active suicidality, a Beck Depression Inventory II suicide item score of \> 2, or a Beck Depression Inventory II total score \> 15~7. Any unstable medical condition which, in the opinion of the investigator, is considered clinically significant or could affect the subject's safety or ability to complete the study~8. Use of a benzodiazepine or other sedative-hypnotic agent (including kava kava or valerian), except for eszopiclone, zaleplon, or zolpidem \< 3 times weekly over the last 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- DUI Court Participants (Type: EXPERIMENTAL): Individuals enrolled in the DUI Court treatment site will be recruited for the 13 week open-label trial of acamprosate.

Based on this trial design, predict the completion outcome and termination type (if applicable).